bioAffinity Technologies (BIAF) announced it has closed the previously announced definitive agreements for the purchase and sale of 720,000 shares of common stock at a purchase price of $2.50 per share in a registered direct offering priced at-the-market under Nasdaq rules. WallachBeth Capital, LLC acted as sole placement agent for the offering. The company intends to use the net proceeds from the offering for working capital, to support expected growing sales for CyPath Lung, its noninvasive test for lung cancer, and general corporate purposes.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIAF:
- BioAffinity Technologies announces $1.8M registered direct offering
- bioAffinity Technologies Reports 95% Sales Surge in Q3 2025
- BioAffinity Technologies reports record growth for CyPath Lung diagnostic test
- bioAffinity Technologies Completes $4.8M Stock Offering
- BioAffinity prices 1.92M common share offering at $2.50 per share